Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction

Oh-Hyun Lee, Seok-Jae Heo, Seong Huan Choi, Ji Woong Roh, Eui Im, Deok-Kyu Cho, Yongcheol Kim · 2026

Read Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction by Oh-Hyun Lee, Seok-Jae Heo, Seong Huan Choi, Ji Woong Roh, Eui Im, Deok-Kyu Cho, Yongcheol Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13578343.txt.

Description

Oh-Hyun Lee and colleagues compare two stomach guard drugs for heart attack patients on twin blood thinners, in a 2026 study of Korean records. After a stent opens a blocked artery, patients take two thinners to stop clots, yet the pair raises the risk of stomach bleeding. Acid blockers guard the stomach, and the team weighed a newer drug, tegoprazan, against the standard class.

Records held more than twenty one thousand patients treated from 2019 to 2022. Before matching, the newer drug group bled less in the gut over one year. After careful matching of like patients, the gut bleeding edge held, major bleeding also ran lower, and rates of repeat heart attack or stroke stayed much the same. The authors frame the newer drug as a safe swap for the standard guard.

Catalog record

CREATOROh-Hyun Lee, Seok-Jae Heo, Seong Huan Choi, Ji Woong Roh, Eui Im, Deok-Kyu Cho, Yongcheol Kim
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30892
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13578343

Browse the full library · About the Tower of Babel